Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

Summary, in English

Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma.

• Author: Jesper Kofoed Damm; Sandra Gordon; Mats Ehinger; Mats Jerkeman; Urban Gullberg; Anne Hultquist; Kristina Drott
• Department/s: Translational lymphoma epigenetics; Division of Hematology and Transfusion Medicine; Division of Clinical Genetics; Tumor microenvironment; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation; Stem Cell Center
• Publishing year: 2015
• Language: English
• Publication/Series: Experimental hematology & oncology
• Volume: 4
• Issue: 4
• Full text: - 607 kB; Download statistics
• Links: http://www.ncbi.nlm.nih.gov/pubmed/25973343?dopt=Abstract; http://dx.doi.org/10.1186/2162-3619-4-4
• Document type: Journal article
• Publisher: BioMed Central (BMC)
• Topic: Hematology; Cancer and Oncology
• Status: Published
• Research group: Translational lymphoma epigenetics
• ISBN/ISSN/Other: ISSN: 2162-3619